Asundexian vs Apixaban on Bleeding Outcomes in Patients With AF
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
Lancet 2022 Apr 09;399(10333)1383-1390, JP Piccini, V Caso, SJ Connolly, KAA Fox, J Oldgren, WS Jones, DA Gorog, V Durdil, T Viethen, C Neumann, H Mundl, MR PatelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.